Investors, CBD Pharma Co. Reach Deal Over Clinical Trial Suit – Law360

Law360 (May 7, 2021, 9:19 PM EDT) — Stockholders pressing consolidated, derivative damage claims against CBD drugmaker Zynerba Pharmaceuticals sought preliminary approval Friday for settlement of a federal suit in Delaware targeting damage to the company from undisclosed adverse effects during a drug trial, in a deal that includes a minimum five-year battery of corporate governance reforms.

The motion in the U.S. District Court for the District of Delaware followed docketing of a proposed $4 million class award in a Pennsylvania federal court for direct damages to stockholders arising from the same adverse episode.

Litigation in Delaware focused on harm to the company from alleged breaches of fiduciary duty, unjust…


Please enter your comment!
Please enter your name here